Rescate de pseudoartrosis asociada a falla de osteosíntesis en fractura femoral por bifosfonatos. Reporte de un caso y revisión de la literatura.

Matias Pereira Duarte; Jonathan Maximiliano Werbner

doi:10.15417/2525-1015.2017.82.712

Matias Pereira Duarte Hospital Italiano de Buenos Aires http://orcid.org/0000-0001-5652-2631
Jonathan Maximiliano Werbner

DOI: https://doi.org/10.15417/2525-1015.2017.82.712

Palabras clave: bifosfonatos, pseudoartrosis, rescate, injerto, osteosíntesis, falla. Bisphosphonates, nonunion, rescue, graft, osteosynthesis, failure.

Resumen

Introducción: Las fracturas asociadas al consumo crónico de bifosfonatos son entidades descriptas recientemente en la literatura médica que presentan altas tasas de pseudoartrosis. Presentamos aquí un caso de rescate de pseudoartrosis de fractura femoral subtrocantérica atípica por bifosfonatos asociada a falla de material de osteosíntesis, tratada finalmente con clavo endomedular cervicodiafisario e injerto estructural de peroné.Presentación del caso: Mujer de 73 años con antecedente de osteoporosis y 6 años de tratamiento con bifosfonatos, sufre una fractura atípica femoral subtrocantérica. Tratada inicialmente en otro centro con placa con tornillo deslizante de cadera. Al cumplirse un año postoperatorio, presenta una falla del material de osteosíntesis asociada a pseudoartrosis del foco de fractura. Presentamos aquí su rescate mediante un clavo cervicodiafisario e injerto óseo autólogo de peroné.Conclusión: El tratamiento con clavo cervicodiafisario más injerto autólogo podría considerarse una técnica efectiva para el tratamiento de la pseudoartrosis en fracturas femorales asociadas a bifosfonatos y déficit de stock óseo.

Biografía del autor/a

Matias Pereira Duarte, Hospital Italiano de Buenos Aires

Universidad Nacional de RosarioResidente del Hospital Italiano de Buenos Aires

Citas

Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC et al. Biphosphonate use and therisk of subtrochantericor femoral shaft in olderwomen. JAMA. 2011; 305(8): 783-789.

Lenart BA, Lorich DG, Lane JM. Atypical Fractures of the Femoral Diaphysis in Postmenopausal Wome nTaking Alendronate. N Engl J Med 2008; 358:1304-1306.

Shane E, Burr D, Ebeling PR, Abrahamsen BO, Adler RA, Brown TD et al. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010; 25: 2267–2294.

Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoSOne 2009; 4(3): e4720.

Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed Bone Turnover by Bisphosphonates Increases Microdamage Accumulation and Reduces Some Biomechanical Properties in Dog Rib. J Bone Miner Res 2000: 15: 613–620.

Unnanuntana A,Saleh A, Mensah KA, Kleimeyer JP, Lane JM. Atypical Femoral Fractures: What Do We Know About Them? AAOS Exhibit Selection. J Bone Joint Surg Am 2013; 95: e8(1-13).

Shane E, Burr D, Abrahamsen Bo, Adler RA, Brown TD, Cheung AM et al. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014; 29: 1–23.

Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs 2011 16; 71(6): 791-814.

Girgis CM, Sher D,Seibel MJ. Atypical Femoral Fractures and Bisphosphonate Use. N Engl J Med 2010; 362: 1848-1849.

Yli-Kyyny T. Bisphosphonates and Atypical Fractures of Femur. J Osteop 2011.

http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203891.htm. FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures.

http://www.fda.gov/Drugs/DrugSafety/ucm229009.htm. FDA Drug Safety Communication: Safety updatefor osteoporosis drugs, bisphosphonates, and atypical fractures.

Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, and Pak CYC. Severely Suppressed Bone Turnover: A Potential Complication of AlendronateTherapy. J Clin Endocr & Metabolism 2005; 90(3): 1294–1301.

Pietrogrande L, Raimondo E. Teriparatide in thetreatment of non-unions: Scientific and clinicalevidences. Injury 2013; 44: S54–S57.

Weil YA1, Rivkin G, Safran O, Liebergall M, Foldes AJ. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma. 2011; 71(1): 186-90.

Issack PS. Bisphosphonate-Associated Subtrochanteric Femoral Fracture with Profound Proximal Cortical Thickening and Canal Narrowing Requiring Blade-PlateFixation. A Report of Two Cases. J Bone Loint Surg. Case Connect 2014; 24: e87

Giannotti S1, Bottai V, Dell'Osso G, De Paola G, Ghilardi M, Guido G. Pseudoarthrosis in atypical femoral fracture: case report. Osteoporos Int. 2013 Nov; 24(11) :2893-5.

Grady MK, Watson JT, Cannada LK. Treatment of Femoral Fracture Nonunion After Long-term Bisphosphonate Use. Orthopedics Jun2012, Vol. 35 Issue 6, pe991.

O'Neill BJ, O'hEireamhoin S, Morrissey DI, Keogh P. Implant failure caused by non-union of bisphosphonate-associated subtrochanteric femur fracture. Case Report. BMJ Case Repapr 2014.

Xue D, Li F, Chen G, Yan S, Pan Z. Do bisphosphonates affect bonehealing? A meta-analysis of randomized controlled trials. J Orthop Surg Res. 2014; 9: 45.